Annual Revenue Comparison: Regeneron Pharmaceuticals, Inc. vs MiMedx Group, Inc.

Biotech Revenue Race: Regeneron vs. MiMedx from 2014-2023

__timestampMiMedx Group, Inc.Regeneron Pharmaceuticals, Inc.
Wednesday, January 1, 20141182230002819557000
Thursday, January 1, 20151872960004103728000
Friday, January 1, 20162450150004860427000
Sunday, January 1, 20173211390005872227000
Monday, January 1, 20183591110006710800000
Tuesday, January 1, 20192992550007863400000
Wednesday, January 1, 20202482340008497100000
Friday, January 1, 202125861500016071700000
Saturday, January 1, 202226784100012172900000
Sunday, January 1, 202332147700013117200000
Monday, January 1, 202414202000000
Loading chart...

Data in motion

A Tale of Two Biotechs: Revenue Trends from 2014 to 2023

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success and market influence. Over the past decade, Regeneron Pharmaceuticals, Inc. has demonstrated a remarkable revenue trajectory, growing from approximately $2.8 billion in 2014 to an impressive $13.1 billion by 2023. This represents a nearly fivefold increase, underscoring Regeneron's robust market position and innovative prowess.

In contrast, MiMedx Group, Inc. has experienced a more modest revenue growth, with figures rising from around $118 million in 2014 to $321 million in 2023. While this growth is significant, it highlights the differing scales and market strategies of these two companies.

This comparison not only reflects the competitive landscape of the biotech industry but also offers insights into the strategic directions and market adaptations of these two distinct players.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025